- Home
- VAL vs NAMS Comparison
VAL vs NAMS Comparison
Compare VAL & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VAL | NAMS |
|---|---|---|
| Founded | 1975 | 2019 |
| Country | Bermuda | Netherlands |
| Employees | 5642 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 3.5B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | VAL | NAMS |
|---|---|---|
| Price | $92.67 | $29.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $63.50 | $46.75 |
| AVG Volume (30 Days) | ★ 1.2M | 829.1K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $25.64 |
| Revenue Next Year | $15.62 | $530.85 |
| P/E Ratio | $16.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.15 | $14.06 |
| 52 Week High | $102.20 | $42.00 |
Technical Indicators
Market Signals| Indicator | VAL | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 57.20 | 39.71 |
| Support Level | $86.46 | $23.48 |
| Resistance Level | $102.20 | $37.43 |
| Average True Range (ATR) | 4.11 | 1.70 |
| MACD | -1.07 | -0.23 |
| Stochastic Oscillator | 54.07 | 13.64 |
Price Performance
Historical ComparisonAbout VAL Valaris Limited
Valaris Ltd is an offshore contract drilling company. The company provides offshore contract drilling services to the international oil and gas industry with operations in almost every offshore market across six continents. Its business consists of four operating segments: Floaters, which includes drillships and semisubmersible rigs; Jackups; ARO; and Other, which consists of management services on rigs owned by third parties. It generates the majority of its revenue from the Floaters segment.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.